Walleye Capital’s Akebia Therapeutics AKBA Stock Holding History

Walleye Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-152,953	Closed	-$418K	–	4512
2025 Q3	$418K	Sell	152,953 -61,864	-29%	-$206K	﹤0.01%	2758
2025 Q2	$782K	Buy	+214,817	New	+$590K	﹤0.01%	2253
2021 Q4	–	Sell	-276,260	Closed	-$796	–	2075
2021 Q3	$796	Sell	276,260 -46,193	-14%	-$132K	0.02%	563
2021 Q2	$1.22K	Buy	322,453 +261,440	+428%	+$880K	0.04%	368
2021 Q1	$207	Buy	61,013 +1,071	+2%	+$3.86K	0.01%	915
2020 Q4	$168	Sell	59,942 -53,188	-47%	-$155K	0.01%	749
2020 Q3	$284K	Buy	+113,130	New	+$993K	0.03%	518
2019 Q4	–	Sell	-7,419	Closed	-$29K	–	1745
2019 Q3	$29K	Buy	7,419 +5,695	+330%	+$24.4K	﹤0.01%	1692
2019 Q2	$8K	Buy	+1,724	New	+$9.81K	﹤0.01%	1607

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's AKBA Position: Q4 2025 in Review

Walleye Capital sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 152,953 shares — an estimated $418K sold.

Walleye Capital first reported a position in AKBA in Q2 2019 and held it in 9 quarters. The position peaked at $782K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Walleye Capital reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 152,953 Akebia Therapeutics shares in Q4 2025, an estimated $418K.
Walleye Capital first reported a position in Akebia Therapeutics in Q2 2019 and held it in 9 quarters.
Walleye Capital's Akebia Therapeutics position peaked at $782K in Q2 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.